Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

BACKGROUND: The pharmacokinetics and appropriate dose regimens of favipiravir are unknown in hospitalized influenza patients; such data are also needed to determine dosage selection for favipiravir trials in COVID-19. METHODS: In this dose-escalating study, favipiravir pharmacokinetics and tolerabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yeming, Zhong, Wu, Salam, Alex, Tarning, Joel, Zhan, Qingyuan, Huang, Jian-an, Weng, Heng, Bai, Changqing, Ren, Yanhong, Yamada, Koichi, Wang, Dayan, Guo, Qiang, Fang, Qiongqiong, Tsutomu, Sakurai, Zou, Xiaohui, Li, Haibo, Gillesen, Annelies, Castle, Lyndsey, Chen, Cheng, Li, Hongyan, Zhen, Jing, Lu, Binghuai, Duan, Jun, Guo, Liping, Jiang, Jinfang, Cao, Ruiyuan, Fan, Guohui, Li, Jintong, Hayden, Frederick G., Wang, Chen, Horby, Peter, Cao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689521/
https://www.ncbi.nlm.nih.gov/pubmed/33232871
http://dx.doi.org/10.1016/j.ebiom.2020.103125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689521/
https://www.ncbi.nlm.nih.gov/pubmed/33232871
http://dx.doi.org/10.1016/j.ebiom.2020.103125

Ejemplares similares